English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aztreonam‐avibactam ( ATM ‐ AVI ) is a promising combination to treat serious infections caused by multidrug‐resistant ( MDR ) pathogens. Three distinct mechanisms of action have been previously characterized for  AVI : inhibition of  ATM  degradation by β‐lactamases, proper bactericidal effect, and enhancement of  ATM  bactericidal activity. The aim of this study was to quantify the individual contribution of each of the three  AVI  effects.  In vitro  static time‐kill studies were performed on four  MDR   Enterobacteriaceae  with different β‐lactamase profiles. β‐Lactamase activity was characterized by measuring  ATM  concentrations over 27 hours. Data were analyzed by a semimechanistic pharmacodynamics modeling approach. Surprisingly, even though  AVI  prevented  ATM  degradation, the combined bactericidal activity was mostly explained by the enhancement of  ATM  effect within clinical range of  ATM  (5–125 mg/L) and  AVI  concentrations (0.9–22.5 mg/L). Therefore, when selecting a β‐lactamase inhibitor for combination with a β‐lactam, its capability to enhance the β‐lactam activity should be considered in addition to the spectrum of β‐lactamases inhibited.

cpt: pharmacometrics and systems pharmacology

Semimechanistic Pharmacodynamic Modeling of Aztreonam‐Avibactam Combination to Understand Its Antimicrobial Activity Against Multidrug‐Resistant Gram‐Negative Bacteria